Brexit Could Make UK A 'Second-Tier State' For Innovative New Drugs, Business Committee Warns
A report from the UK House of Commons business committee on its inquiry into the impact of Brexit on the pharma sector has flagged up the multiple challenges facing companies and regulators.
You may also be interested in...
The UK government has published its response to the concerns raised by a parliamentary health committee about the impact of Brexit on medicines and medical devices. However, the response is lacking in detail, and the biotech industry says it does not provide the information companies need to be able to plan for the future.
The pharmaceutical sector has given its backing to a report from MPs which warns that a no-deal Brexit will have a hugely damaging effect on the industry in the country, turning it into "a second-tier state for new and innovative medicines."
Pharmaceutical companies have been urged by the European Commission to press ahead with their contingency planning for Brexit, amid signs some firms are taking a “wait-and-see” approach.